Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

Shares in biopharmaceutical stock Bristol Myers Squibb ($BMY) remained healthy today despite scrapping its partnership with California-based blood ...

Bristol Myers Squibb Stock (BMY) Looks Healthier After Ditching Blood Cancer Partner

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) is launching a Phase 1 stud...

Bristol-Myers Squibb Adds Early Alzheimer’s Antibody To Its Long-Term Growth Story

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1 Study to Evaluate the Mass Ba...

Bristol‑Myers Squibb Advances Navlimetostat Metabolism Study, Signaling Steady Pipeline Progress

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY), Enovis (ENOV) and Lant...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Enovis (ENOV) and Lantheus (LNTH)

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb today and set a price target of $70.00. According to TipRanks, Meacham ...

Citi Remains a Hold on Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb (BMY) is launching a Phase 1 study ca...

Bristol-Myers Squibb Expands Kidney Pipeline With New Golcadomide Renal Study

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb (BMY) has launched a Phase 4 study in...

BMY Expands Melanoma Immunotherapy Footprint With New Phase 4 Trial in India

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is launching a new study to track rea...

Bristol-Myers Squibb Tracks Real-World Use of Luspatercept in Anemia Care

In a report released on August 4, Trung Huynh from RBC Capital maintained a Hold rating on Bristol-Myers Squibb, with a price target of $64.00. The...

Bristol-Myers Squibb (BMY) Gets a Hold from RBC Capital

Shares in British pharma giant AstraZeneca ($AZN) jumped about 5% on Wednesday morning while those in top U.S. biopharma company Bristol Myers ($BM...

No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal

RBC Capital analyst Trung Huynh maintained a Hold rating on Bristol-Myers Squibb yesterday and set a price target of $64.00. The company’s shares c...

Bristol-Myers Squibb (BMY) Receives a Hold from RBC Capital

Scotiabank analyst Louise Chen maintained a Hold rating on Bristol-Myers Squibb today and set a price target of $60.00. According to TipRanks, Chen...

Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Illumina (ILMN), Dyne Therapeutics (DYN) and Brist...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Illumina (ILMN), Dyne Therapeutics (DYN) and Bristol-Myers Squibb (BMY)

Today, several major companies are expected to report earnings: Altria Group (MO), Amazon (AMZN), Apple (AAPL), Bristol-Myers Squibb (BMY), Enterpr...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$67.81	-0.16%	3.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$67.81	-0.2%	3.23M
3
4
5
6

BMY

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel